Literature DB >> 2032732

Monoclonal antibodies to the soluble human IL-6 receptor: affinity purification, ELISA, and inhibition of ligand binding.

D Novick1, H Engelmann, M Revel, O Leitner, M Rubinstein.   

Abstract

Soluble IL-6 receptor (IL-6-R) purified to homogeneity from normal human urine was used for immunization of mice and rabbits. Spleen cells derived from a mouse showing a high binding titer to IL-6-R in an inverted solid phase radioimmunoassay (IsRIA) and in a Western blotting analysis were fused to mouse myeloma cells. The hybridomas were screened by the IsRIA, and 30 positive clones were isolated and characterized. They were suitable for affinity purification of the IL-6-R and for its detection by Western blot analysis, by ELISA and by sandwich type sRIA. Most of them inhibited the binding of labeled IL-6-R to IL-6 in a solid phase RIA.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2032732     DOI: 10.1089/hyb.1991.10.137

Source DB:  PubMed          Journal:  Hybridoma        ISSN: 0272-457X


  8 in total

1.  Test of a novel transparent floating carrier by recombinant cho cells expressing sIL6 receptor protein.

Authors:  D Gurari-Rotman; Z Marks; J Chevath; M Revel; N G Maroudas
Journal:  Cytotechnology       Date:  2001-10       Impact factor: 2.058

Review 2.  Interleukin-6: structure-function relationships.

Authors:  R J Simpson; A Hammacher; D K Smith; J M Matthews; L D Ward
Journal:  Protein Sci       Date:  1997-05       Impact factor: 6.725

3.  Identification of a novel antigenic structure of the human receptor for interleukin-6 involved in the interaction with the glycoprotein 130 chain.

Authors:  J P Gaillard; J Liautard; J C Mani; J M Fernandez Suarez; B Klein; J Brochier
Journal:  Immunology       Date:  1996-09       Impact factor: 7.397

4.  Serum soluble interleukin 6 (IL-6) receptor and IL-6/soluble IL-6 receptor complex in systemic juvenile rheumatoid arthritis.

Authors:  F De Benedetti; M Massa; P Pignatti; S Albani; D Novick; A Martini
Journal:  J Clin Invest       Date:  1994-05       Impact factor: 14.808

5.  Live Borrelia burgdorferi preferentially activate interleukin-1 beta gene expression and protein synthesis over the interleukin-1 receptor antagonist.

Authors:  L C Miller; S Isa; E Vannier; K Georgilis; A C Steere; C A Dinarello
Journal:  J Clin Invest       Date:  1992-09       Impact factor: 14.808

6.  High circulating levels of biologically inactive IL-6/SIL-6 receptor complexes in systemic juvenile idiopathic arthritis: evidence for serum factors interfering with the binding to gp130.

Authors:  P Pignatti; L Ciapponi; P Galle; M B Hansen; M Massa; C Meazza; G Paonessa; D Novick; G Ciliberto; A Martini; F De Benedetti
Journal:  Clin Exp Immunol       Date:  2003-02       Impact factor: 4.330

7.  C-reactive protein: a physiological activator of interleukin 6 receptor shedding.

Authors:  S A Jones; D Novick; S Horiuchi; N Yamamoto; A J Szalai; G M Fuller
Journal:  J Exp Med       Date:  1999-02-01       Impact factor: 14.307

8.  Interleukin-6 and interleukin-6 receptor secretion by chronic lymphatic leukaemia and normal B lymphocytes: effect of PMA and PWM.

Authors:  I Drucker; A Klajman; M Revel; Y Manor; S Ben-Efraim; D Novick
Journal:  Mediators Inflamm       Date:  1997       Impact factor: 4.711

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.